8-K 1 b412677_8k.htm FORM 8-K Prepared and filed by St Ives Financial

 

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

_______________________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 5, 2006

Savient Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

Delaware 0-15313 13-3033811



(State or other juris-
diction of incorporation
(Commission
File Number)
(IRS Employer
Identification No.)


One Tower Center, 14th Floor
East Brunswick, New Jersey 08816

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (732) 418-9300

Not applicable

(Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
  Pre-commeYncement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))
   
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(b)      Effective as of April 5, 2006, Carl E. Kaplan has retired from his position as a member of the Board of Directors of Savient Pharmaceuticals, Inc. Mr. Kaplan’s letter of retirement is set forth in exhibit 17.1.

Item 9.01. Financial Statements and Exhibits.

(d)      Exhibits

          See Exhibit Index attached hereto.

 


 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  SAVIENT PHARMACEUTICALS, INC.
     
Date: April 10, 2006 By: /s/ Philip K. Yachmetz
   
    Philip K. Yachmetz
Executive Vice President &
Chief Business Officer

 

 


 

EXHIBIT INDEX

Exhibit No. Description  
 
17.1 Letter of Retirement from Carl E. Kaplan, dated April 5, 2006.